Review articleInflammatory processes in Alzheimer's disease
Section snippets
Alzheimer's disease
As the most common neurodegenerative disorders, Alzheimer's disease (AD) currently affects 20 to 30 million individuals worldwide (Selkoe, 2005). AD accounts for most cases of dementia that are diagnosed after the age of 60 years of life. In the US, the number reaches roughly 4 million patients. The prevalence of AD increases with age, affecting approximately 1% to 3% of the population in the 6th decade of life, 3% to 12% of the population between 70 and 80 years, and up to 25 to 35% older than
Inflammation and AD
Although Aβ has been considered to play a key role in AD pathogenesis (Walsh et al., 2002b, Walsh and Selkoe, 2004), it remains still uncertain whether Aβ plaques and neurofibrillary tangles are causative for AD. These doubts are fueled by the finding that the Aβ plaque burden poorly correlates with the progression and severity of dementia in AD. Moreover, transgenic animals that develop widespread Aβ plaque deposition in response to overexpression of APP mutations show only slight cognitive
Immunostimulators in Alzheimer's disease
While minor signs of neuroinflammation can be found in the normal aging brain, the AD brain faces a much stronger activation of inflammatory systems indicating that an increasing amount or qualitatively different immunostimulants are present. Cumulative evidence suggests that Aβ peptides play a pivotal role as inducers of neuroinflammation. However, chromogranin and several other proteins may contribute to this induction.
Cellular components of neuroinflammation in Alzheimer's disease
Microglia cells represent the brain innate immune system and hence the first line of defense when challenged by bacterial, viral or fungal infection. Although these functions are of major importance and beneficial, it has become clear that microglial activation may also be evoked by endogenous proteins and can significantly contribute to neuronal damage. Along with microglia, astrocytes and even neurons are directly reacting and contributing to the chronic neuroinflammatory changes in AD.
Pro- and antiinflammatory mediators
The neuroinflammatory response observed in AD is characterized by a whole array of pro- and antiinflammatory mediators including members of the complement cascade, chemo- and cytokines as well as inflammatory enzyme systems. Several of these factors may promote neurodegenerative mechanisms while others may rather limit ongoing inflammatory changes or even exert beneficial neurotrophic effects. Thus, not a single mediator but rather the entire spectrum of inflammatory agents will determine
Inflammatory cytokines
The cytokine class of inflammatory mediators is secreted by microglia and astrocytes surrounding β-amyloid neuritic plaques. Cytokines associated with AD include several interleukins (ILs), TNF-α and TGFβ along with several others. Their production is increased in inflammatory states and they function by regulating the intensity and duration of the immune response (Tuppo and Arias, 2005).
In astrocytes, IL-1 induces IL-6 production, stimulates iNOS activity (Rossi and Bianchini, 1996), and
Inflammation-permissive factors in AD
Occurrence and deposition of aggregated, misfolded or phosphorylated proteins may play the pivotal role for the induction and ongoing stimulation of inflammation in the AD brain. However, since some of these proteins may well occur in the normal aging brain without evoking such a dramatic immune response, it may be hypothesized that several other changes in AD are facilitating inflammation. Loss of aminergic brains stem nuclei, such as the locus ceruleus and the nucleus basalis of Meynert, may
Cytokine driven feedback mechanisms
Apart from self-propagation and direct cytopathic effect on neurons, cytokines may more directly contribute to AD related neurodegeneration. Thus, studies performed in transgenic animals suggest that cerebral amyloid deposition is increased under inflammatory conditions (Games et al., 1995, Guo et al., 2002). Moreover, these animals do not develop amyloid plaques unless inflammation is induced suggesting that inflammatory molecules either raise the susceptibility for Aβ deposition and
Functional and structural consequences of neuroinflammation in AD
Over the past decade, numerous lines of evidence have strongly suggested that neuroinflammation contributes to AD pathogenesis. Irregardless at which time point of the disease it occurs, it seems clear that once initiated, inflammatory pathomechanisms can affect the AD brain. Functional and structural consequences may be differentiated to understand the various levels at which inflammation may contribute to AD.
Antiinflammatory treatment strategies
Neuroinflammatory changes may even occur at early stages in the AD brain and significantly contribute to the pathogenesis of the disease. This raises the question whether therapeutic strategies can be developed which successfully target the ongoing inflammation.
Conclusions and future directions
Increasing evidence suggests that inflammation significantly contributes to the pathogenesis of AD. The generation and secretion of proinflammatory mediators may interact at multiple levels with neurodegenerative mechanisms. Thus, several proinflammatory cytokines cannot only induce neuropathic mechanisms and thereby contribute to neuronal death, but are also able to influence classical neurodegenerative pathways such as APP processing. The concomitant release of antiinflammatory mediators may
References (324)
- et al.
Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice
J. Neuroimmunol.
(2002) - et al.
In vitro detection of S-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-1-[6-[2-[18F]fluoroethylmethylamino]-2-naphthyl]ethylidenemalono nitrile
Neuroscience
(2003) - et al.
Inflammation and Alzheimer's disease
Neurobiol. Aging
(2000) - et al.
TGF-beta1, regulation of Alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization
Mol. Brain Res.
(1999) - et al.
PPAR gamma is required for placental, cardiac, and adipose tissue development
Mol. Cell
(1999) - et al.
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984
Mayo Clin. Proc.
(1998) - et al.
Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice
J. Biol. Chem.
(2004) - et al.
Immunological aspects of microglia: relevance to Alzheimer's disease
Neurochem. Int.
(2001) - et al.
Evidence for glial-mediated inflammation in aged APPSW transgenic mice
Neurobiol. Aging
(1999) - et al.
Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1–40 and Abeta1–42 by human astrocytes
Neurobiol. Dis.
(2000)
Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells
Neurobiol. Dis.
Microglial-produced nitric-oxide and reactive nitrogen-oxides mediate neuronal cell-death
Brain Res.
Cognitive function in young and adult IL interleukin-6 deficient mice
Behav. Brain Res.
Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal
Neurobiol. Aging
Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
Neurobiol. Aging
Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective
Mol. Cell. Neurosci.
In-vivo measurement of activated microglia in dementia
Lancet
Effect of a carboxy-terminal fragment of the Alzheimer's amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells
Life Sci.
Chromogranin A induces a neurotoxic phenotype in brain microglial cells
J. Biol. Chem.
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
Neurobiol. Aging
Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal–glial cortical cultures
Neuropharmacology
Nitric oxide synthase induction in glial cells: effect on neuronal survival
Life Sci.
The role of complement and activated microglia in the pathogenesis of Alzheimer's disease
Neurobiol. Aging
Inflammatory mechanisms in Alzheimer's disease
Trends Pharmacol. Sci.
Noradrenergic regulation of inflammatory gene expression in brain
Neurochem. Int.
Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
Biochem. Pharmacol.
Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals
Neuroscience
Norepinephrine increases I kappa B alpha expression in astrocytes
J. Biol. Chem.
Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice
Brain Res.
Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus
J. Chem. Neuroanat.
Inflammatory factors are elevated in brain microvessels in Alzheimer's disease
Neurobiol. Aging
Changes in the brain catecholamines in patients with dementia of Alzheimer type
Br. J. Psychiatry
Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial
JAMA
Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs
J. Alzheimer's Dis.
Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis
J. Neurochem.
Production of hemolymphopoietic cytokines Il-6, Il-8, colony-stimulating factors by normal human astrocytes in response to Il-1-beta and tumor-necrosis-factor-alpha
J. Immunol.
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study
Neurology
Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology
Brain Res.
C-terminal fragment of amyloid precursor protein induces astrocytosis
J. Neurochem.
Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
Nature
Beta-amyloid precursor protein mismetabolism and loss of calcium homeostasis in Alzheimers-disease
Alzheimers Dis.: Amyloid Precursor Proteins Signal Transduct. Neuronal Transplant.
Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation
Proc. Natl. Acad. Sci. U. S. A.
Microglia kill amyloid-beta1–42 damaged neurons by a CD14-dependent process
Neuroreport
Expression and regulation of cyclooxygenase-2 in rat microglia
Eur. J. Biochem.
CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity
Nat. Neurosci.
PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis
Ann. Neurol.
TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs
FASEB J.
Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase BACE-1
J. Neural Transm.
Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease
Alzheimer Dis. Assoc. Disord.
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
Nature
Cited by (633)
An immunological puzzle: The adaptive immune system fuels Alzheimer's disease pathology
2024, Brain, Behavior, and ImmunityEffect of diet and nutrition on neuroinflammation: An overview
2023, Diet and Nutrition in Neurological DisordersThe molecular pathology of neurodegenerative and psychiatric disorders
2023, Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders